Value vs risk, page-14

Hey Gav, the "A" in CellPryme-A remains a mystery still, of course, despite yesterday's news and has yet to come out of stealth mode and be disclosed by the company.

I'm still conflicted over whether CellPryme-A is the "automation" bit or "activation". Your remark, "I totally love yesterdays announcement with plans to utilise mechanism rather than viruses to have the omnicar DNA transferred into immune cells" tends to make me think its "A" for "Activation".

Was your choice of word "mechanism" carefully selected, perhaps?

CellPryme-Activation and CellPryme-Manufacturing is my final decision. Makes sense given that both have been in R&D for the last 18mths and the designing of the automation system is ahead of us over the next 12 mths. I'm of the belief too that our OmniCAR and CP platforms can be used in both Allogeneic and Autologous cell therapy applications. What are your thought's, Gav?